01:17:55 Europe / Stockholm

Kurs & Likviditet

Kursutveckling och likviditet under dagen för detta pressmeddelande


2025-03-06 Kvartalsrapport 2025-Q2
2024-11-08 Årsstämma 2025
2024-09-20 Bokslutskommuniké 2024
2024-03-07 Kvartalsrapport 2024-Q2
2023-11-17 X-dag ordinarie utdelning HEALTH 0.00 EUR
2023-11-16 Årsstämma 2024
2023-09-28 Bokslutskommuniké 2023
2023-04-24 Extra Bolagsstämma 2023
2023-03-23 Kvartalsrapport 2023-Q2
2022-11-17 Årsstämma 2023
2022-10-25 X-dag ordinarie utdelning HEALTH 0.00 EUR
2022-09-29 Bokslutskommuniké 2022
2022-06-29 Extra Bolagsstämma 2022
2022-02-24 Kvartalsrapport 2022-Q2
2021-10-29 X-dag ordinarie utdelning HEALTH 0.00 EUR
2021-10-28 Årsstämma 2022
2021-09-15 Bokslutskommuniké 2021


ListaFirst North Finland
Nightingale Health är verksamt inom medicinteknik. Bolaget är specialiserat inom utveckling av medicintekniska produkter. Produktportföljen är bred och inkluderar plattformar och tjänster inom blodanalyser som används i sjukdomsförebyggande syfte. Utöver huvudverksamheten erbjuds även service och tillhörande kringtjänster. Verksamheten drivs globalt med störst närvaro inom Europa.
2024-05-23 09:45:00

Company release

23 May 2024 at 10:45 a.m. (EEST)

Nightingale Health Plc's ("Nightingale Health") Board of Directors resolved toextend the subscription period of option rights in the stock option program for key employees. The subscription period of option rights in the stock option program for key employees ended on 31 December 2023, and the Board of Directors resolved to continue the subscription period until 31 December 2028.

The size of the stock option program remains the same and no new stock options were issued. All terms and conditions for the employee stock option program also remain unchanged. 

The stock option program for key employees was launched in March 2022 based on the authorisation granted by the Extraordinary General Meeting held on 18 February 2021. The total number of option rights that can be issued based on the stock option program for key employees is 2.5 million stock options and each option right entitles the option holder to subscribe for one Series B share. The right to subscribe shares is earned solely based on reaching market capitalisation steps of at least EUR 500 million and EUR 1,000 million calculated with the volume weighted average price.

By the end of 2023, approximately 45% of the 2.5 million stock options were unused and remain in the stock option pool. The decision to continue the subscription period was done to enable the continuous use of stock options in recruitments and incentivizing key employees to contribute to the growth and value increase of the company.

For further information, please contact:

Teemu Suna, CEO

Certified advisor:

Oaklins Merasco Ltd, tel. +358 9 6129 670

About Nightingale Health

Nightingale Health's mission is to build sustainable healthcare and reduce health inequalities. Nightingale Health has developed the world's most advanced health check that provides risk detection for multiple chronic diseases from a single blood sample. Nightingale's Health Check can be scaled to entire populations at a low cost, and it can replace many of the current clinical risk assessments. Detecting disease risks on a population level allows for the effective targeting and tracking of health interventions, and better prevention of the onset of chronic diseases. With every sample we help to create a healthier world.

Nightingale Health operates globally with a parent company in Finland and seven subsidiaries in countries such as Japan, the United States, Singapore, and the United Kingdom. Nightingale Health has customers in more than 34 countries in the healthcare and medical research sectors. The company's technology is being used in many of the world's leading health initiatives, such as the UK Biobank, and over 600 peer-reviewed publications validate the technology. The company's Series B shares are listed on the First North Growth Market Finland marketplace. Read more: https://nightingalehealth.com